Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03229200 · ClinicalTrials.gov registry record · Phase 4
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
A Phase 4 study of Solid Tumor and Lymphoma, Non-Hodgkin, sponsored by Pharmacyclics Switzerland.
- Active
- Registry status
- Phase 4
- Development phase
- 297
- Enrollment target
- 20
- Study locations
NCT03229200 is a Phase 4 study of Solid Tumor and Lymphoma, Non-Hodgkin that is active but no longer recruiting, run by Pharmacyclics Switzerland. The registered enrollment target is 297 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (35% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT03229200, a Phase 4 study of Solid Tumor and Lymphoma, Non-Hodgkin, is active but no longer recruiting, sponsored by Pharmacyclics Switzerland.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 297 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
Conditions Studied
Interventions
- DRUG Ibrutinib
Study Locations (20)
California
- Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center - Burbank
- City Of Hope National Medical Center - Duarte
- UCSD Moores Cancer Center - La Jolla
- University of California Los Angeles (UCLA) - Los Angeles
- Stanford University - Stanford
New York
- Northwell Health - New Hyde Park
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical College-New York Presbyterian Hospital - New York
- University of Rochester - Rochester
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
North Carolina
- Levine Cancer Institute - Charlotte
- Southeastern Medical Oncology Center - Goldsboro
Georgia
- Emory University - Atlanta
Kentucky
- Norton Medical Plaza II, 3991 Dutchmans Lane - Louisville
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2027-05-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03229200
The ClinicalTrials.gov registry entry for NCT03229200 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (35% higher). The listed sponsor is Pharmacyclics Switzerland, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Ibrutinib is the first listed.
NCT03229200 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Illinois.
Frequently Asked Questions
What is clinical trial NCT03229200 about?
NCT03229200 is a clinical study titled "Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.". Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their regio...
What is the current status of trial NCT03229200?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 297 participants. The study started on 2017-05-22. Estimated completion is 2027-05-10.
What conditions does trial NCT03229200 study?
This clinical trial studies the following conditions: Solid Tumor, Lymphoma, Non-Hodgkin, Graft Vs Host Disease, Lymphoma, B-Cell, Leukemia, B-cell.
What interventions are being tested in trial NCT03229200?
The interventions under investigation include: Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03229200?
This trial is sponsored by Pharmacyclics Switzerland, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03229200 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Durvalumab Long-Term Safety and Efficacy Study
COMPLETED · Phase 4
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.